These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 2132193)

  • 1. Hyperparathyroid bone disease in diabetic renal failure.
    Cundy TF; Humphreys S; Watkins PJ; Parsons V
    Diabetes Res; 1990 Aug; 14(4):191-6. PubMed ID: 2132193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A; Naderi AS
    Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.
    Coen G; Mazzaferro S; Costantini S; Ballanti P; Carrieri MP; Giordano R; Smacchi A; Sardella D; Bonucci E; Taggi F
    Miner Electrolyte Metab; 1989; 15(5):295-302. PubMed ID: 2811788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcitropic hormonal status in north Indian patients with end-stage renal disease.
    Singh AK; Avula S; Kher V; Rao DS; Mithal A
    Natl Med J India; 1999; 12(5):202-7. PubMed ID: 10612998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Osteocalcin in chronic hemodialysis patients as an additional parameter in the diagnosis of advanced secondary hyperparathyroidism].
    Motz W
    Acta Med Austriaca; 1989; 16(1):8-12. PubMed ID: 2785325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
    Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients--importance of glycaemic control.
    Ishimura E; Okuno S; Kitatani K; Kim M; Shoji T; Nakatani T; Inaba M; Nishizawa Y
    Diabetologia; 2002 Oct; 45(10):1446-8. PubMed ID: 12378387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome.
    Malluche HH; Goldstein DA; Massry SG
    J Clin Invest; 1979 Mar; 63(3):494-500. PubMed ID: 429568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between parathyroid hormone, bone alkaline phosphatase and N-telopeptide of type 1 collagen in diabetic and non-diabetic haemodialysis patients.
    Takahashi N; Kojima T; Ogawa H; Ishiguro N
    Nephrology (Carlton); 2007 Dec; 12(6):539-45. PubMed ID: 17995578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary hyperparathyroidism in chronic renal failure.
    Malmaeus J
    Scand J Urol Nephrol Suppl; 1983; 70():1-63. PubMed ID: 6351238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of diabetes mellitus, age, and duration of dialysis on parathormone in chronic hemodialysis patients.
    Nasri H; Kheiri S
    Saudi J Kidney Dis Transpl; 2008 Jul; 19(4):608-13. PubMed ID: 18580021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parathyroid hormone in patients with diabetes mellitus and end-stage renal disease on chronic haemodialysis.
    Pabico RC; Rivero AJ; McKenna BA; Freeman RB
    Proc Eur Dial Transplant Assoc; 1983; 19():221-6. PubMed ID: 6878235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone disease in analgesic nephropathy.
    Fassett RG; Lien JW; McClure J; Mathew TH
    Clin Nephrol; 1982 Dec; 18(6):273-9. PubMed ID: 7151345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal bone disorders in children: therapy with vitamin D3 or 1,25-dihydroxycholecalciferol.
    Bulla M; Delling G; Offermann G; Ziegler R; Benz G; Lühmann H; Sanchez de Reutter A; Severin M
    Proc Eur Dial Transplant Assoc; 1979; 16():644-8. PubMed ID: 232917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone disease in renal failure. Clinical and histomorphometric studies.
    Nilsson P
    Scand J Urol Nephrol Suppl; 1984; 84():1-68. PubMed ID: 6393322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bone involvement in primary oxalosis. Study of 20 cases].
    Benhamou CL; Bardin T; Tourlière D; Voisin L; Audran M; Edouard C; Lafage MH; Sebert JL; de Vernejoul MC; Wendling D
    Rev Rhum Mal Osteoartic; 1991 Nov; 58(11):763-9. PubMed ID: 1780651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.